Top Story Today
Lilly's Two-Drug Obesity Combo Just Smashed the Scale (and Maybe Some Stomachs)
Patients on Eli Lilly's new obesity combo lost an average of 54 pounds in 48 weeks, nearly 20 pounds more than Zepbound alone. The secret weapon: eloralintide, a drug that mimics the hormone amylin, paired with Zepbound's tirzepatide to hit appetite control from two different angles. But the victory lap comes with a serious asterisk. Up to 27% of patients in the highest-dose group dropped out because of side effects, mostly GI issues like nausea. If one in four patients can't tolerate it, those record-setting averages only tell half the story.
Why it matters: Amylin-based combos are emerging as the next frontier in obesity treatment, pushing weight loss well past what GLP-1 drugs achieve alone. Lilly and Novo Nordisk are both racing to own this space, and the winner could define the next decade of the obesity market.
Read more →Clinical Wins and Setbacks
A First-of-Its-Kind Survival Win for Bispecific T-Cell Engagers in Lung Cancer
Adding Amgen's tarlatamab to AstraZeneca's durvalumab significantly extended survival in first-line small cell lung cancer, a disease where fewer than 10% of patients reach five years. It's the first time a bispecific T-cell engager (a molecule that physically drags immune cells to cancer cells) has shown a survival benefit in a solid tumor setting. Full data are pending, but the milestone could open the floodgates for this entire drug class.
Read more →A Patient Death Haunts BMS's Fibrosis Drug, and Nobody Knows Who's to Blame
Bristol Myers Squibb disclosed a fatal liver event in its Phase 3 trial for admilparant, a fibrosis drug targeting the LPA1 receptor. The trial is still blinded, so it's unclear whether the patient was even on the drug or placebo. A prior BMS compound targeting the same receptor was abandoned over liver toxicity, making this signal especially uncomfortable for the entire LPA1 drug class.
Read more →Roche's Brain-Penetrating MS Pill Earns Fast-Track FDA Review
The FDA granted Priority Review to Roche's fenebrutinib for both relapsing and primary progressive MS, a first for any BTK inhibitor. Unlike infusion-based therapies, this pill crosses into the brain to target smoldering neuroinflammation. A decision is expected in Q1 2027, and liver enzyme elevations remain the key risk to watch.
Read more →Genentech's Oral Pill Cuts Breast Cancer Progression Risk by 62% in Key Subgroup
Published in the NEJM, giredestrant paired with everolimus slashed disease progression risk by 62% in breast cancer patients with ESR1 mutations, the genetic changes that help tumors dodge standard therapy. Roche already has an FDA application under review, setting up a showdown with Lilly's imlunestrant, which got to market first.
Read more →Merck's $10.8 Billion Bet Just Proved TL1A Works Beyond the Gut
Tulisokibart, the antibody Merck acquired with Prometheus Biosciences, posted a 72% response rate in a Phase 2 trial for hidradenitis suppurativa (chronic, painful skin boils), more than doubling the placebo rate. It's the first positive dermatology readout for the red-hot TL1A drug class, validating Merck's thesis that this target works across multiple organs.
Read more →Deals, Policy, and Big Bets
HHS Wants to Replace the Clinical Trial Relay Race with a Continuous Sprint
HHS unveiled its biggest clinical trial overhaul in decades, launching two programs that use AI and "phaseless" trial designs to eliminate dead time between development stages. The vision: predictive models, real-time data analysis, and shared infrastructure. The risk: critics warn faster doesn't always mean safer, and AI-driven eligibility decisions could entrench health disparities.
Read more →Sanofi Writes Regeneron a $1 Billion Check for Drugs That Barely Exist Yet
Sanofi paid $1 billion upfront (with up to $8 billion total) for four early-stage Regeneron antibody programs, three of which are preclinical. All four target type 2 inflammation, the same biology behind their shared blockbuster Dupixent. It's one of the largest upfront payments ever for assets this early, signaling urgency to build the sequel to a franchise worth billions.
Read more →Viking's Obesity Drug Retains Most Weight Loss on Less Frequent Shots
Patients who switched from weekly to every-other-week VK2735 injections kept up to 97% of their weight loss, compared to 61% on placebo. In a market where every competitor requires weekly needles, less frequent maintenance dosing could be the convenience edge that reshapes adherence. Phase 3 results are expected in the second half of 2027.
Read more →$251 Million to Make Drugs Where There's No Gravity
Varda Space Industries closed a $251 million Series D at a $1.6 billion valuation to manufacture pharmaceuticals in orbit. The startup has already completed six missions, crystallizing drugs in microgravity and returning them to Earth in hypersonic capsules. It sounds wild, but the science is real: zero-gravity crystallization produces more uniform particles that could improve drug stability and delivery.
Read more →